360 Stem Cell & Regenerative Medicine Newsletter- January 06, 2016

 weSRCH's Best of the Internet Award

Share: FacebookTwitterLinkedIn

360 Stem Cell & Regenerative Medicine Newsletter - Jan 06, 2016

Featured video Stanford Football:

Pac-12 Champions and Stem Cell Researchers
“Before standout seniors offensive guard Joshua Garnett and wide receiver Michael Rector pursue professional football, they have prepared for their careers in medicine while conducting stem cell biology research at Stanford University under Dr. Michael Longaker.” 360 Editor’s note: Starting the year with a feel-good video. Happy 2016!

World Stem Cell Summit

The Japan Times: SEIZE THE WORLD / Yamanaka- Prioritize Patients Above Papers
Nobel Laureate Dr. Shinya Yamanaka provided an illuminating interview stating, “I always keep my original vision to perform, to do ‘science.’ It does not mean writing or publishing papers, but helping patients by making new therapies. I think that experience in my early days is very important in my science.”

Nikkei Asian Review: Japan Drugmakers Turn to Regenerative Medicine for Edge
The linked article summarizes some of the larger deals evidencing how Japan’s pharmaceutical companies are investing in RegMed. Takeda Pharmaceutical, Sumitomo Dainippon Pharma, Astellas and FujiFilm Holdings are mentioned.


NPR: Gene Editing Tool Hailed As A Breakthrough, And It Really Is One- Editing DNA has Never Been Easier
“Simply put, CRISPR-Cas9 allows scientists to make specific changes to specific genes in living cells. Such a thing was possible in the past using techniques called zinc finger nucleases and Talens. But those techniques were cumbersome and weren't widely adopted. In the three short years since the first scientific papers appeared about CRISPR-Cas9, the technique has been ‘spreading like wildfire,’ says Ramesh Akkina, a molecular immunologist at Colorado State University. And for 2015, the journal Science called CRISPR the breakthrough of the year.”

Tech Insider: 5 Terrible Illnesses that Genetic Engineering Could Eliminate Forever
According to Dr. Eric Lander, the list includes: HIV, some forms of genetic blindness, familial hypercholesterolemia, sickle-cell anemia and hemophilia.

Featured video from the Business Insider:

Watch science writer Carl Zimmer explain CRISPR in 90 seconds.

360 Editor’s Comment: While the animations depicting CRISPR on a molecular scale are informative, what the world really needs is a series of videos showing actual scientists doing the task of gene editing utilizing the CRISPR technology. Step by step, please. If any 360 readers are aware of such a video posted online, please send me a link!


Science AAAS: CRISPR Helps Heal Mice with Muscular Dystrophy
“The red-hot genome editing tool known as CRISPR has scored another achievement: Researchers have used it to treat a severe form of muscular dystrophy in mice. Three groups reported in Science that they wielded CRISPR to snip out part of a defective gene in mice with Duchenne muscular dystrophy (DMD), allowing the animals to make an essential muscle protein. The approach is the first time CRISPR has been successfully delivered throughout the body to treat grown animals with a genetic disease.”

GEN: CRISPR Works Well but Needs Upgrades- More Effective and Reliable CRISPR Tools Will Have To Be Developed
In an excellent article, MaryAnn Labant explains how CRISPR will have to overcome a number of practical obstacles. The article summarizes some of the more effective and reliable CRISPR tools that will have to be developed.


Xconomy: Bayer, CRISPR Therapeutics Form $335M+ Gene Editing Venture
“Bayer and CRISPR Therapeutics, which has offices in Cambridge, MA, and the U.K., will create a joint venture to discover and develop drugs for blood disorders, blindness, and congenital heart disease. The joint venture doesn’t have a name as of yet, but it’ll be based in London with an office in Cambridge, MA. Bayer is paying $35 million up front for a minority stake in CRISPR Therapeutics, and will fund the joint venture with at least $300 million in R&D investments over the next five years. Bayer will get 50 percent of the rights to drugs for blindness, blood disorders, and congenital heart disease that come out of the deal. It’ll also get access to delivery technologies that the new venture comes up with.”

South Florida Business Journal: University of Miami School of Medicine Receives Massive Donation for Stem Cell Research
The Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine led by Dr. Joshua Hare has received a $25 million donation from the Soffer Family Foundation. This marks the largest gift ISCI has received to date


UTHealth Researchers Study Stem Cell Treatments for Children with CP
A first-of-its-kind clinical trial studying two forms of stem cell treatments for children with cerebral palsy (CP) has begun at The University of Texas Health Science Center at Houston (UTHealth) Medical School. The double-blinded, placebo-controlled study’s purpose includes comparing the safety and effectiveness of banked cord blood to bone marrow stem cells.

360 Newsletter Editor

Bernard Siegel
Executive Director
Genetics Policy Institute

2013 World Stem Cell Summit

About GPI

The nonprofit Genetics Policy Institute (GPI) seeks to establish a positive policy, regulatory and societal framework to enable research to flourish, under the highest ethical and medical standards. We seek to accelerate the discovery and development of lifesaving cures and therapies to alleviate human suffering due to chronic and terminal afflictions. Visit Website.

ConnectGPI on FacebookGPI on TwitterGPI on LinkedIn

Genetics Policy Institute (GPI) and the Regenerative Medicine Foundation (RMF) Announce Merger Plan

Domain: Medical
Category: Biology
weSRCH App on Apple

Recent Newsletters

12 March, 2019
10 October, 2018
15 February, 2018